Sanofi Gets Priority U.S. FDA Review for Sutimlimab Product
1 min read
Sanofi Gets Priority U.S. FDA Review for Sutimlimab Product
French healthcare company Sanofi said on Thursday that the U.S. Food & Drug Administration (FDA) regulator had granted a priority review for Sanofi’s sutimlimab product, which treats hemolysis in adults suffering from cold agglutinin disease.